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OBJectiVe Gamma Knife surgery (GKS) is one of the surgical alternatives for the treatment of drug-resistant trigemi-
nal neuralgia (TN). This study aims to evaluate the safety and efficacy of GKS in a large population of patients with TN 
with very long-term clinical follow-up.
methOdS Between July 1992 and November 2010, 737 patients presenting with TN were treated using GKS. Data 
were collected prospectively and were further retrospectively evaluated at Timone University Hospital. The frequency 
and severity of pain, as well as trigeminal nerve function, were evaluated before GKS and regularly thereafter. Radiosur-
gery using the Gamma Knife (model B, C, 4C, or Perfexion) was performed with the help of both MR and CT targeting. 
A single 4-mm isocenter was positioned in the cisternal portion of the trigeminal nerve at a median distance of 7.6 mm 
(range 4–14 mm) anterior to the emergence of the nerve (retrogasserian target). A median maximum dose of 85 Gy 
(range 70–90 Gy) was prescribed.
reSultS The safety and efficacy are reported for 497 patients with medically refractory classical TN who were 
never previously treated by GKS and had a follow-up of at least 1 year. The median age in this series was 68.3 years 
(range 28.1–93.2 years). The median follow-up period was 43.8 months (range 12–174.4 months). Overall, 456 patients 
(91.75%) were initially pain free in a median time of 10 days (range 1–180 days). Their actuarial probabilities of remaining 
pain free without medication at 3, 5, 7, and 10 years were 71.8%, 64.9%, 59.7%, and 45.3%, respectively. One hundred 
fifty-seven patients (34.4%) who were initially pain free experienced at least 1 recurrence, with a median delay of onset 
of 24 months (range 0.6–150.1 months). However, the actuarial rate of maintaining pain relief without further surgery was 
67.8% at 10 years. The hypesthesia actuarial rate at 5 years was 20.4% and at 7 years reached 21.1%, but remained 
stable until 14 years with a median delay of onset of 12 months (range 1–65 months). Very bothersome facial hypesthe-
sia was reported in only 3 patients (0.6%).
cONcluSiONS Retrogasserian GKS proved to be safe and effective in the long term and in a very large number of 
patients. Even if the probability of long-lasting effects may be modest compared with microvascular decompression, the 
rarity of complications prompts discussion of using GKS as the pragmatic surgical first- or second-intention alternative 
for classical TN. However, a randomized trial, or at least a case-matched control study, would be required to compare 
with microvascular decompression.
http://thejns.org/doi/abs/10.3171/2015.2.JNS142144
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Trigeminal neuralgia (TN), also known as “tic dou-loureux,” is a serious health problem with a preva-lence of 12.6 per 100,000 people.44 Patients typi-
cally describe a severe and sudden pain in the face like an 
electric shock. While the etiology remains unclear, there is 
growing evidence supporting the fact that in most patients 
one of the main causal factors resides in the compression 
of the trigeminal nerve root, close to its entry into the pons 
by an aberrant arterial or venous loop.19
According to the most recent classification of the Inter-
national Headache Society,10 classical trigeminal neuralgia 
(CTN) must be distinguished from symptomatic TN. CTN 
includes all cases without an established etiology, i.e., the 
idiopathic cases, as well as cases with potential vascular 
compression of cranial nerve V.10 Drug therapy is the first 
line of treatment and offers adequate pain relief in many 
patients.41 Carbamazepine (highest level of evidence) and 
oxcarbazepine (best tolerance) are the most commonly 
prescribed drugs for the treatment of TN.5 A minority of 
patients have hypersensitivity reactions, with some forms 
being associated with substantial morbidity and mortality. 
In Northern Europeans, the HLA-A*3101 allele is associ-
ated with carbamazepine-induced hypersensitivity reac-
tions.20 Patients who do not respond to medical therapy 
or have intolerable adverse effects are suitable candidates 
for surgery.41 Surgical treatments include microvascular 
decompression (MVD), percutaneous ablative procedures 
that produce a partial lesion of the nerve (thermocoagula-
tion, microcompression, and glycerol injection), and radio-
surgery.21 MVD tackles the presumed cause by separating 
the offensive vessel loop from the trigeminal nerve and is 
currently considered as the gold-standard surgical treat-
ment for drug-resistant TN.1
Radiosurgery is a minimally invasive neurosurgical 
approach. The concept of radiosurgery was first intro-
duced by Lars Leksell in 1951 when he treated a patient 
suffering from essential TN using a prototype guiding 
device linked to a dental x-ray machine.16 Later, Leksell 
conceived the Gamma Knife, a tool dedicated to radio-
surgery that uses multiple focusing beams from cobalt-60 
sources.15 Several retrospective studies6,13 and a few pro-
spective studies32 have reported good short-term and mid-
term safety and efficacy of Gamma Knife surgery (GKS) 
for TN. GKS is known to be the least invasive neurosurgi-
cal approach for medically refractory TN.5,9 However, the 
long-term outcomes have not been well documented.6,13,43
methods
type of Study
The study was designed as an open, self-controlled, 
noncomparative study.30 A case report form was created 
and was completed prospectively when the first patient 
was treated at Timone University Hospital. Clinical ex-
aminations and MRI were performed (the later to exclude 
secondary cases). Data were retrospectively analyzed. 
Permission from the ethics committee was obtained for 
this historical cohort study.
patients
From July 1992 through November 2010, 737 patients 
presenting with intractable TN were prospectively se-
lected and treated with radiosurgery at Timone Univer-
sity Hospital in Marseille, France. A total of 497 patients 
had more than 1 year of follow-up. We excluded from 
our final analysis patients with TN secondary to multiple 
sclerosis,37 megadolichobasilar artery compression,39 or a 
second GKS treatment,40 which are reputed to have more 
variable responses to radiosurgery and were beyond the 
scope of this study.
Basic demographic data
The median patient age was 68.3 years (range 28.1–93.2 
years); 225 patients (45.3%) were men and 272 (54.7%) 
were women. Pain was on the right side in 267 patients 
(53.7%) and on the left side in 230 patients (46.3%). Only 
19 patients (3.8%) had bilateral pain, but never simulta-
neously. Pain was predominantly distributed in the V2 
territory of the trigeminal nerve (29.4%), followed by V2 
and V3 (24.5%), V3 (19.5%), V1 and V2 (13.9%), V1, V2, 
and V3 (6.8%), V1 (5.4%), and V1 and V3 (0.02%) ter-
ritories (Table 1). All patients presented with typical pain 
according to further described criteria (i.e., TN1; please 
see Diagnostic Criteria Using the International Head-
ache Society Definitions). The median time between pain 
onset and radiosurgery treatment was 68.3 months (range 
6–531 months). Preoperative MRI revealed the presence 
of a vascular compression in 278 cases (55.9%). Twenty-
six patients (5.2%) died but were not excluded from the 
study because they had at least 1 year of follow-up, as did 
the other patients enrolled in the study.
details of previous treatments 
One hundred seventy-three (34.8%) patients had prior 
surgical procedures, of which 102 (20.5%) patients had 
only 1 previous intervention, 41 (8.2%) patients had 2 
previous surgeries, and 30 (6%) had 3 or more previous 
surgeries.
Previous surgeries consisted of radiofrequency ablation 
in 99 (19.9%) patients, balloon microcompression in 64 
(12.9%) patients, MVD in 45 (9.1%) patients, and glycerol 
rhizotomy in 6 (1.2%) patients.
Before GKS, 107 (21.5%) patients had sensory distur-
bance in relation to a previous surgical procedure, which 
consisted of slight hypesthesia in 99 (19.9%) and severe 
hypesthesia in 8 (1.6%) patients. GKS was the first sur-
gical procedure in 324 patients (65.2%). All patients had 
drug-resistant TN or major intolerance to all therapies. 
Two hundred sixty-three patients (52.9%) reported sub-
stantial side effects to drug therapy at the time of radio-
surgery.
diagnostic criteria using the international headache 
Society Definition
All patients fulfilled the criteria of the International 
Headache Society.10 Evaluation of the type of TN was 
made according to the classifications proposed by Eller 
et al.7 and comprised idiopathic TN1 and TN2. TN1 is de-
scribed as typically sharp, shooting, electrical shock like, 
with pain-free intervals between attacks that is present for 
more than 50% of the time; TN2 is described as an ach-
J Neurosurg  Volume 124 • April 20161080
radiosurgery in classical trigeminal neuralgia
ing, throbbing, or burning pain that is present for more 
than 50% of the time and is constant in nature (constant 
background pain being the most significant attribute). 
Only patients fulfilling the criteria for the TN1 type were 
included. The preoperative MRI protocol included 3D T1-
weighted images, with and without contrast, and T2 CISS 
(constructive interference in steady state) without contrast.
Brief description of the Operative technique
All patients underwent GKS. After application of the 
Leksell model G stereotactic frame (Elekta Instruments 
AB) under local anesthesia, all patients underwent ste-
reotactic MRI and CT for target definition. The MRI se-
quences used to identify the trigeminal nerve were T2-
type semi-millimetric CISS (Siemens) without contrast 
and contrast-enhanced T1-weighted images. Bone CT 
routinely supplements the neuroradiological investigation 
to correct any distortion errors on the MRI images.32,38
Between July 1992 and November 2010, models B, C, 
4C, or Prefexion of the Gamma Knife were successively 
used (Elekta Instruments AB).
A single 4-mm isocenter was used in all patients and 
positioned in the anterior cisternal portion of the trigemi-
nal nerve at a median distance of 7.6 mm (range 4–14 mm) 
anterior to the emergence of the nerve (retrogasserian tar-
get). This target has been classically used in our center 
since the beginning of GKS treatments for TN, as detailed 
in previous studies.29,30,32,33
The median value of the maximum dose delivered was 
85 Gy (70–90 Gy). Furthermore, we initially give a dose 
of 90 Gy at the 100% isodose. Beam channel blocking is 
used depending on the maximal dose received by 10 mm3 
of the brainstem. If this dose is more than 15 Gy, we di-
minish the dose, and then if still necessary we start beam 
channel blocking to make it possible for us to avoid the 
so-called “Flickinger effect” (increasing the mean dose to 
the nerve also increases toxicity).8 All interventions were 
performed by the senior neurosurgeon (J.R.).
Follow-up monitoring
Initial follow-up was based on clinical evaluations per-
formed at regular intervals of 3 months, 6 months, and 1 
year after the treatment and on a yearly basis thereafter. 
All patients were seen in person for the proper evaluation 
of safety and efficacy, including facial sensory testing, 
corneal reflex, and jaw motility. For long-term follow-up 
updates, telephone interviews were considered acceptable 
for patients unable to visit us either because of distance or 
general health-related conditions.
The patients and referring doctor were instructed to 
continue the medication unchanged for at least 1 month, 
and then were instructed to diminish the drug doses pro-
gressively in cases of pain freedom. Every clinical evalu-
ation made by our medical team during the follow-up 
course was prospectively noted in the database so that we 
had continuous and prospective up-to-date information. 
The 15 types of essential data, as considered by Zakrze-
wska and Thomas48 for articles reporting the outcomes of 
the surgical treatment for TN, were followed and are pre-
sented hereafter. At our center, systematic MR follow-up 
has never been part of our protocol.
Explicit Definitions of Outcome Measures
Outcome measures included initial pain freedom, on-
set of the sensory disturbance, recurrence, and recurrence 
without further surgery. Efficacy is reported according to 
the Barrow Neurological Institute (BNI) scale (Class I, no 
trigeminal pain and no medication; Class II, occasional 
pain not requiring medication; Class IIIa, no pain but con-
tinued medication; Class IIIb, controlled with medication; 
Class IV, some pain but not adequately controlled with 
medication; Class V, severe pain and no pain relief). A 
successfully treated patient was pain  free without medica-
tion (BNI Class I).
The degree of hypesthesia is reported using the BNI fa-
taBle 1. clinical preoperative and demographic data
Variable Value*
Sex
  Male 225 (45.3)
 Female 272 (54.7)
Median age (yrs) (range) 68.3 (28.1–93.2)
Median duration of follow-up (mos) (range) 43.8 (12–174.4) 
Side of pain
  Right 267 (53.7)
  Left 230 (46.3)
Pain distribution
 V2 146 (29.4)
  V2 & V3 122 (24.5)
  V3 97 (19.5)
 V1 & V2 69 (13.9)
  V1 & V2 & V3 34 (6.8)
 V1 27 (5.4)
  V1 & V3 1 (0.02)
Preop MRI vascular conflict (other than  
  megadolichobasilar compression)
278 (55.9)
No prior surgery 324 (65.2)
Prior surgery 173 (34.8)
 1 102 (20.5)
 2 41 (8.2)
  ≥3 30 (6)
Type of prior surgery
  Radiofrequency lesion 99 (19.9)
  Balloon microcompression 64 (12.9)
  Microvascular decompression 45 (9.1)
  Glycerol rhizotomy 6 (1.2)
Side effects from prior surgery 107 (21.5)
Facial sensitivity before GKS
  Normal 393 (79.1)
  Slight hypesthesia 96 (19.3)
  Severe hypesthesia 8 (1.6)
  Anesthesia 1 (0.02)
*  Values indicate the number of patients (%) unless otherwise indicated.
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cial hypesthesia scale (Class I, no facial numbness; Class 
II, mild facial numbness and not bothersome; Class III, 
facial numbness and somewhat bothersome; Class IV, fa-
cial numbness and very bothersome).34 The corneal reflex 
was assessed in all patients. Additionally, the appearance 
of dysesthesias, allodynias, paresthesias, anesthesia do-
lorosa, masseteric weakness, neurological complications 
outside of the trigeminal nerve territory, systemic compli-
cations, and death were carefully noted.
Recurrence was defined as change from Class I to a low-
er outcome class. Thus, the situation of a patient who had 
been pain free without medication (Class I) and who then 
restarted taking specific drugs but who remained pain free 
on medication (Class II) was considered as a recurrence.
The latency intervals to becoming pain free or devel-
oping recurrence or a sensory disturbance, the dates of 
medication changes, and the dates of further surgical pro-
cedures were also carefully monitored.
Definition of Minor and Major Recurrence
A minor recurrence was defined as one that was well 
tolerated by the patient (lower pain frequency and inten-
sity) that did not require a new surgical therapy. A major 
recurrence was defined as requiring a further surgical 
procedure. We use the term “initial efficacy” when a pa-
tient is pain free with or without medication in the first 6 
months after the radiosurgery and has no recurrence in the 
year that follows the procedure.
The probability of maintaining pain relief with further 
surgery will be separately reported in our clinical study.
patient Satisfaction
Patient satisfaction was evaluated at the last follow-up 
through a simple questionnaire. The items proposed as an 
answer in our semistructured questionnaire included: “No 
regret, I would have radiosurgery again with no hesita-
tion;” “No opinion;” and “I regret performing radiosur-
gery (and would not do it again).”
Statistical analysis
All statistical analyses were performed using R soft-
ware (version 2.12.0, R Foundation for Statistical Com-
puting). The survival R package was used for the survival 
analysis. For the evaluation of outcomes such as pain free, 
hypesthesia, and recurrence, the time-to-event was esti-
mated using the Kaplan-Meier method. Bivariate analy-
sis was then performed to identify the predictive factors 
among the collected variables. For qualitative variables, 
Kaplan-Meier curves were used to graphically represent 
survival among the different groups and compared using 
the univariate log-rank test. For all variables, the effects 
were estimated and tested by fitting univariate Cox pro-
portional hazards regression models. The proportionality 
of the hazards was assessed graphically by log cumulative 
hazard plots. For qualitative variables, the chi-square test 
was performed when valid; otherwise the exact Fischer 
test was used. For quantitative variables, the Mann-Whit-
ney test was performed given the number of patients. All 
tests were 2-sided, and p values < 0.05 were judged to be 
significant.
results
details of Follow-up period
The median follow-up period was 43.8 months (range 
12–174.4 months).
initial rate of pain Freedom response
Four hundred fifty-six patients (91.75%) were initially 
pain free in a median time of 10 days (range 1–180 days). 
The initially pain-free actuarial rates at 0.5, 1, 2, 3, 4, 5, 
and 6 months were 53.52%, 73%, 83.5%, 88.1%, 88.9%, 
89.5%, and 91.75%, respectively (Fig. 1; with the flat part 
of the curve being practically reached at 6 months).
The following characteristics showed a negative and 
statistically significant difference: previous surgical inter-
vention (p = 0.005, HR 0.24, and 95% CI 0.09–0.65), only 
1 previous surgical intervention (p = 0.009, HR 0.16, and 
95% CI 0.04–0.64), and a previous history of MVD (p = 
0.01, HR 0.64).
Differences in age (p = 0.172), time elapsed until treat-
ment onset (p = 0.731), and the sides of pain (p = 0.4) were 
not statistically significant.
postoperative Sensory assessment: details of Other 
postoperative complications 
No patient experienced an early complication after 
GKS. Seventy-two patients (21.1% actuarial rate) later 
developed sensory dysfunction such as paresthesias or 
objective facial sensory loss, which occurred especially 
during the first 5 years after GKS. The time of onset of 
hypesthesia occurred at a median of 12 months (range 
1–65). Patients had either mild hypesthesia in 49 (8.3%) 
cases or severe in 23 (4.6%) cases. We also assessed hyp-
esthesia using the BNI facial hypesthesia scale: mild fa-
cial numbness in 61 (12.3%) patients; facial numbness that 
Fig. 1. Probability of an initial pain-free onset depending on the time 
since GKS. The probability of being initially pain free reaches a plateau 
at 6 months (with a rate of freedom from pain of 91.75%). The initial 
pain-free actuarial rates at 0.5, 1, 2, 3, 4, 5, and 6 months were 53.52%, 
73%, 83.5%, 88.1%, 88.9%, 89.5%, and 91.75%, respectively.
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was somewhat bothersome in 8 (1.6%) patients; and facial 
numbness that was very bothersome in 3 (0.6%) patients.
The 3 patients with very bothersome hypesthesia said 
that their quality of life was worse and that this dysfunc-
tion was not a good tradeoff, whereas the majority of the 
patients who developed numbness after GKS (69 of 72 
patients; 95.8%) considered that their quality of life im-
proved after GKS and that the sensory dysfunction was a 
good tradeoff for pain relief.
The hypesthesia actuarial rates at 0.5, 1, 2, 3, 5, and 7 
years were 6.4%, 10.2%, 16.8%, 18.3%, 20.4%, and 21.1%, 
respectively, and remained stable for 14 years (Fig. 2). No 
patients developed a trigeminal motor deficit after GKS or 
other cranial nerve deficits. There were 0 cases of anesthe-
sia dolorosa or dry-eye syndrome.
management and results of recurrent pain
One hundred fifty-seven (34.4%) of the patients who 
were initially pain free (456 patients) experienced at least 
1 recurrence after GKS. The median time to recurrent 
pain was 24 months (range 0.6–150.1 months). Because of 
recurrent medically refractory pain, 112 (22.5%) patients 
required further surgeries. Eighty-five (17.1%) patients re-
quired only 1 further surgery, 21 (4.2%) required 2 further 
surgeries, and 6 (1.6%) required 3 or more surgeries.
In our unit, the most common intervention after failed 
GKS was balloon microcompression, which was per-
formed in 61 (12.3%) patients, followed by thermocoagu-
lation in 29 (5.8%) patients, MVD in 21 (4.2%) patients, 
and glycerol rhizotomy in 1 (0.02%) patient (Table 2).
Usually, in our clinic, if a first-intention MVD treat-
ment was proposed but declined by the patient in the ab-
sence of efficacious GKS, it is usually proposed again and 
frequently accepted by the patient.
The actuarial probabilities of maintaining pain relief 
without medication at 0.5, 1, 2, 3, 5, 7, 10, 12, and 14 years 
were 93.4%, 85.9%, 78.6%, 71.8%, 64.9%, 59.7%, 45.3%, 
40.7%, and 33.9%, respectively (see Fig. 3). Having three 
or more previous surgeries was a factor associated with 
decreased long-term efficacy (p = 0.0163; HR 1.98; 95% CI 
1.13–3.47) in comparison with patients having undergone 
fewer than 2 prior surgeries. Post-GKS hypesthesia onset 
was associated with a higher probability of maintaining 
pain relief (p = 0.0003; HR 0.27; 95% CI 0.13–0.56).
probability of maintaining pain relief without Further 
Surgery
The actuarial probabilities of maintaining pain re-
lief without further surgery at 0.5, 1, 2, 3, 5, 7, and 10 
years were 96.1%, 92.1%, 88.1%, 84.2%, 79.7%, 75.4%, 
and 67.8%, respectively, and remained stable through 14 
years (Fig. 4). We found statistically significant data for 3 
or more previous surgeries (p = 0.007; HR 2.64; 95% CI 
1.3–5.37) and the presence of post-GKS hypesthesia (p = 
0.006; HR 0.06; 95% CI 0.01–0.46).
postoperative patient Satisfaction 
The vast majority of patients (93.8%) expressed a high 
level of satisfaction, did not regret undergoing GKS, and 
would undergo the procedure again. A minority of the pa-
tients had no opinion (4.6%), and 2.3% would not undergo 
the procedure again.
discussion
There are several neurosurgical therapeutic options for 
Fig. 2. Actuarial probability of having new-onset hypesthesia depend-
ing on the time since GKS. The hypesthesia actuarial rates at 0.5, 1, 2, 
3, 5, and 7 years were 6.4%, 10.2%, 16.8%, 18.3%, 20.4%, and 21.1%, 
respectively, and remained stable for 14 years.
taBle 2. postoperative assessment 
Variable Value*
Initially pain free 456 (91.75)
Post-GKS sensory dysfunction 72 (14.5)
  Mild 49 (9.8)
  Severe 23 (4.6)
BNI facial hypesthesia scale
  No facial numbness 425 (85.5)
  Mild facial numbness 61 (12.3)
  Facial numbness, somewhat bothersome 8 (1.6)
  Facial numbness, very bothersome 3 (0.6)
Recurrence of pain 157 (34.4)
Median time to pain recurrence in mos (range) 24 (0.6–150.1)
Additional treatment after GKS 112 (22.5)
  No. of treatments
  1 85 (17.1)
  2 21 (4.2)
    ≥3 6 (1.2)
  Type of treatment
    Balloon microcompression 61 (12.3)
    Radiofrequency lesion 29 (5.8)
    Microvascular decompression 21 (4.2)
    Glycerol rhizotomy 1 (0.02)
*  Values indicate the number of patients (%) unless otherwise indicated.
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drug-resistant CTN. Radiosurgery was first used for TN 
treatment in the 1960s by Lars Leksell.16 Its safety and ef-
ficacy started to be evaluated in the early 1990s, including 
by our team.28,31 A cornerstone paper was the multicentric 
study of Kondziolka et al., which appeared in 199612 and 
generated a profound paradigm shift in radiosurgical prac-
tice.33 The reappraisal of radiosurgery for TN in the 1990s 
was made possible by the development of high-resolution 
MRI, which enabled the proper visualization of the cister-
nal portion of cranial nerve V.30,33 Radiosurgery is current-
ly regarded as the least invasive neurosurgical approach for 
TN.5,9,44 A trigeminal nerve deficit usually appears within 
the first 2 years after radiosurgery, but has also been re-
ported as late as 5 years after treatment.13 The only side 
effect reported in our long-term study is trigeminal nerve 
sensory disturbance. Only 21.5% of the patients reported 
this side effect, and the vast majority did not consider it 
as bothersome or disabling. The mechanisms of action of 
radiosurgery for TN are not known. Several authors have 
reported a higher rate of pain relief in patients experienc-
ing hypesthesia.25 However, contrary to the percutaneous 
techniques, it is noteworthy to point out that the majority 
of the patients experiencing long-term pain freedom in our 
study did not report hypesthesia. Consequently, we do not 
consider hypesthesia necessary for the efficacy of radio-
surgery. In the meta-analysis by Gronseth et al.,9 the rate 
of hypesthesia reported after radiosurgery is similar to the 
rate of hypesthesia after MVD and much lower than the 
rate of hypesthesia reported after percutaneous ablative 
procedures. This observation suggests that radiosurgery 
may involve a mechanism of action that is more subtle 
than a purely destructive one.
The technical nuances of GKS have a major impact on 
the clinical outcome of radiosurgery for TN.33 Pain control 
increases according to the dose prescription, but a larger 
volume of nerve treated has been reported to dramatically 
increase the toxicity (i.e., the risk of bothersome hypes-
thesia) without increasing the rate of pain relief.8 Also, a 
target placed close to the brainstem at the level of the root 
entry zone26 seems to be associated with a higher risk of 
numbness and higher risk of bothersome hypesthesia. This 
fact is confirmed by the recent paper by Sheehan et al.42 
who found more numbness in a group of patients where 
the target used was the so-called dorsal root entry zone in 
comparison with the more anterior cisternal target that the 
authors used later on in their series. The major impact of 
these technical nuances may explain the large variability 
in the safety and efficacy reported in the literature. Of note, 
the remarkable high response rate in our series (initial pain 
freedom rate of 91.3% at 6 months) and low hypesthesia 
rate on a long-term basis are likely due to the use of a high 
maximum prescription dose (median 85 Gy) and use of the 
“anterior retrogasserian target.”
There are only 3 studies reporting long-term outcome 
after GKS.6,13,43 Dhople et al.6 described the outcomes for 
102 patients, with a median follow-up of 5.6 years (range 
13–115 months). The target was the dorsal root entry zone 
with a median maximal dose of 75 Gy (range 70–80 Gy). 
Regarding the classical outcomes, the initial pain freedom 
rate was 81%, bothersome hypesthesia rate was 6% (the 
global rate not reported), and the probabilities of maintain-
ing pain relief at 3, 5, and 7 years were 41%, 34%, and 22%, 
respectively.
Kondziolka et al.13 reported the outcomes for 503 pa-
tients, of whom 107 had more than 5 years of follow-up. 
The target was placed at “3–8 mm anterior from the junc-
tion of the trigeminal nerve and pons.” The maximal dose 
delivered was 80 Gy. Regarding the classical outcomes: 
the initial pain freedom rate was 89%; sensory dysfunction 
Fig. 3. Actuarial probability of maintaining pain relief without medication. 
The actuarial probabilities of maintaining pain relief at 0.5, 1, 2, 3, 5, 7, 
10, 12, and 14 years were 93.4%, 85.9%, 78.6%, 71.8%, 64.9%, 59.7%, 
45.3%, 40.7%, and 33.9%, respectively.
Fig. 4. Actuarial probability of maintaining pain relief without new 
surgery depending on the time since pain cessation. The actuarial prob-
abilities of maintaining pain relief without further surgery at 0.5, 1, 2, 3, 
5, 7, and 10 years were 96.1%, 92.1%, 88.1%, 84.2%, 79.7%, 75.4%, and 
67.8%, respectively, and remained stable for 14 years.
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appeared in 10.5% of patients with 1 case of deafferenta-
tion pain (in a patient who already had decreased facial 
sensation after previous MVD); and the probabilities of 
maintaining pain relief at 3, 5, and 10 years were 71%, 
46%, and 30%, respectively.
Young et al.43 reported outcomes for 315 patients with 
a mean duration of follow-up of 68.9 ± 41.8 months. The 
target was placed “on the trigeminal nerve, with the 20% 
isodose line tangential to the pontine surface.” All patients 
were treated with a maximal dose of 90 Gy. Regarding the 
classical outcomes, initial pain-freedom rate was found in 
85.6% of cases, and hypesthesia was found in 32.9% (and 
very bothersome in 4.5%) of cases. Furthermore, dry-eye 
syndrome was encountered in 22.4% and jaw weakness in 
11.2% of patients.
The gold-standard neurosurgical procedure is MVD. 
Although no prospective randomized trial exists, MVD 
seems to be the approach that provides the highest chance 
of maintaining long-term pain relief.17,27 MVD is not ex-
pected to damage the nerve, but presumably acts by al-
leviating the pathophysiological cause of TN, namely, 
compression of the trigeminal nerve by a vascular loop. 
MVD carries a small but definite risk of major, including 
fatal, complications. In 1996, Barker et al.1 reported the 
retrospective evaluation of a large cohort of 1155 patients 
treated with MVD and followed up for at least 1 year (me-
dian follow-up 6.2 years). Thirty percent of the patients 
experienced recurrence of pain. Due to severe recurrence, 
11% of patients underwent a second operation. The major 
complications reported by the authors included 2 post-
operative deaths (0.2%), 1 brainstem infarction (0.1%), 4 
intracerebral hematomas, 4 cerebellar edemas, 2 cases of 
hydrocephalus, 12 cases of facial palsy (2 permanent), 15 
cases of extraocular muscle palsy (2 permanent), 16 cases 
of ipsilateral hearing loss, 22 cases of severe facial numb-
ness, 20 cases of CSF leakage, 4 cases of pseudomeningo-
cele, 5 cases of bacterial meningitis, 225 cases of chemi-
cal meningitis, 2 cases of pneumonia, and 1 case each of 
septicemia, myocardial infarction, transverse sinus throm-
bosis, pulmonary embolus, and permanent contralateral 
hearing loss.1 Few other reports2,24,47,48 used independent 
outcome assessments after MVD.5 These case series con-
firm the results of Barker et al., with a 75% chance of 
maintaining pain relief at 3 years and a risk of operative 
mortality of 0.2% (rising to 0.5% in other reports).1 Ma-
jor problems such as CSF leakage, infarcts, or hematomas 
are reported in 4% of the patients, and aseptic meningitis 
in 11%; diplopia due to injury to cranial nerves IV and 
VI (most frequently transient) and facial palsy are rare.2,47 
Ipsilateral hearing loss is a major long-term complication 
that has been reported in as many as 10% of patients.2,47 
Sensory loss is observed in 7% of patients.
Percutaneous techniques (thermocoagulation, balloon 
microcompression, and glycerol injection) share an ab-
lative mechanism of action. All of these procedures re-
quire brief general anesthesia, the penetration of a probe 
through the foramen ovale under fluoroscopic control or 
navigation, and a physical action (thermal, mechanical, 
or chemical) on the fibers of cranial nerve V at the level 
of the gasserian ganglion. Generating a certain level of 
hypesthesia is classically necessary for the complete and 
prolonged efficacy of these techniques. Thus, all these 
percutaneous techniques are associated with a high rate of 
more or less disabling trigeminal nerve dysfunction. In the 
main series of the literature (see Lopez et al.18), the 3-year 
actuarial rate of complete pain relief has been reported 
as 58% to 64% for radiofrequency thermocoagulation,18,45 
53% to 54% for glycerol rhizolysis,23,36 and 69% for bal-
loon microcompression.3 Masticatory weakness has been 
reported in 12% of patients after thermocoagulation14,18,45 
and in 3% after glycerol rhizolysis.23,35,36 Troublesome dys-
esthesia has been reported in 4% of patients after thermo-
coagulation,11,14,45 in 8.5% after glycerol rhizolysis,4,23 and 
in 10% after balloon microcompression.22 Anesthesia do-
lorosa has been reported in 1.5% of patients after thermo-
coagulation,11,14,45 2.5% after glycerol rhizolysis23,35,36 and 
has not been reported after balloon microcompression.22 
Keratitis is observed was 1.5% of patients after thermo-
coagulation11,14,45 and 2% after glycerol rhizolysis23,35,36 but 
was not reported after balloon microcompression.22 It is 
important to note that with all these neurosurgical pro-
cedures, postoperative morbidity is lower in high-volume 
units.
Very few Level I evidence papers concerning the evalu-
ation of the different surgical techniques for the treatment 
of TN are available.44 The quality of reporting evaluations 
of surgical treatments for TN rarely follow the recommen-
dations published in 2003 by Zakrzewska and Lopez.46
conclusions
The present study is unique due to the fact that the data 
were collected in a prospective fashion, the cohort is very 
large, and a long-term follow-up was conducted; however, 
this study is still limited by the absence of randomization. 
This series represents, to date, the study with the largest 
case series available and has the advantage of a very long-
term follow-up. Additionally, this study brings to light the 
fact that the percentage of bothersome hypesthesia is low 
(0.3%) using a range of doses between 70 and 90 Gy with 
the retrogasserian target. This study provides reasonable 
long-term evidence of the very high safety and efficacy 
of GKS in CTN. Radiosurgery is a rational first-line neu-
rosurgical option for TN. The spectrum of complications 
clearly differs between different neurosurgical options and 
must be taken into account during the decision-making 
process. The rarity of the complications and the impor-
tant probability of long-lasting effects prompt us to regard 
GKS as a pragmatic surgical first- and/or second-intention 
alternative for CTN. However, MVD remains as the ref-
erence technique, and further prospective randomized 
studies are still needed to compare the long-term efficacy 
of radiosurgery with MVD. We expect these studies to 
clarify the potential role of each approach. Neurosurgical 
techniques offer the highest chance of improving quality 
of life in patients with medically refractory TN. However, 
surgery is not indicated for all these patients; they should 
be informed about the full range of choices, and they must 
integrate the benefits and risks of each alternative in the 
decision-making process. The centers able to provide pa-
tients with all these techniques are better placed to con-
tribute to these clarifications.
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